Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

Abstract: Parallelize a computer program by scoping program variables at compile time and inserting code into the program. Identify as value predictable variables, variables that are: defined only once in a loop of the program; not defined in any inner loop of the loop; and used in the loop. Optionally also: identify a code block in the program that contains a variable assignment, and then traverse a path backwards from the block through a control flow graph of the program. Name in a set all blocks along the path until a loop header block. For each block in the set, determine program blocks that logically succeed the block and are not in the first set. Identify all paths between the block and the determined blocks as failure paths, and insert code into the failure paths. When executed at run time of the program, the inserted code fails the corresponding path.

Abstract: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

Abstract: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

Abstract: Methods and apparatus provide for a workload adjuster to estimate the startup cost of one or more non-main threads of loop execution and to estimate the amount of workload to be migrated between different threads. Upon deciding to parallelize the execution of a loop, the workload adjuster creates a scheduling policy with a workload for a main thread and workloads for respective non-main threads. The scheduling policy distributes iterations of a parallelized loop to the workload of the main thread and iterations of the parallelized loop to the workloads of the non-main threads. The workload adjuster evaluates a start-up cost of the workload of a non-main thread and, based on the start-up cost, migrates a portion of the workload for that non-main thread to the main thread's workload.

Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract: A computer program is speculatively parallelized with transactional memory by scoping program variables at compile time, and inserting code into the program at compile time. Determinations of the scoping can be based on whether scalar variables being scoped are involved in inter-loop non-reduction data dependencies, are used outside loops in which they were defined, and at what point in a loop a scalar variable is defined. The inserted code can include instructions for execution at a run time of the program to determine loop boundaries of the program, and issue checkpoint instructions and commit instructions that encompass transaction regions in the program. A transaction region can include an original function of the program and a spin-waiting loop with a non-transactional load, wherein the spin-waiting loop is configured to wait for a previous thread to commit before the current transaction commits.

Abstract: The present invention is directed to 2-cycloalkylamino-4-arylamino-benzamide compounds of formula I pharmaceutically acceptable salts thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder.

Abstract: A method and mechanism for producing and executing self-steering program code. A method comprises analyzing program code and identifying portions which may be amenable to optimization. Having identified such a portion of code, at least one optimized version of the identified code is added to the program code. Additionally, a selection mechanism is added to the program code which is configured to select between two or more versions of the portion of code during runtime. The modified program code is then compiled with the added optimized version and the selection mechanism. During execution, monitoring of behavior of the code may be enabled or disabled. Based upon such monitored behavior, a different version of the code may be selected for execution. Various optimized versions may be selected for execution in a manner which takes advantage of the current behavior of the program.

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.

Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Abstract: The present invention is directed to compounds represented by Formula (I) or a pharmaceutically acceptable salt, ester, or prodrug thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat certain conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

Abstract: A system and method for minimizing register spills during compilation. A compiler reallocates spilled variables from stack memory to other available registers. Although a corresponding register file may not have available registers for storage, the compiler identifies available registers in other locations for storage. The compiler identifies available registers in an alternate register file, wherein the alternate register file may be a floating-point register file which is then used for spilled integer variables. Other instruction type combinations between spilled variables and alternate register files are possible. When an available register within the alternate register file is identified, the compiler modifies the program instructions to allocate the corresponding spilled variable to the available register.

Abstract: One embodiment of the present invention provides a system for communicating and performing synchronization operations between a main thread and a helper-thread. The system starts by executing a program in a main thread. Upon encountering a loop which has associated helper-thread code, the system commences the execution of the code by the helper-thread separately and in parallel with the main thread. While executing the code by the helper-thread, the system periodically checks the progress of the main thread and deactivates the helper-thread if the code being executed by the helper-thread is no longer performing useful work. Hence, the helper-thread is executes in advance of where the main thread is executing to prefetch data items for the main thread without unnecessarily consuming processor resources or hampering the execution of the main thread.

Abstract: The present invention is directed to compounds of formula (I) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to intermediates used in making such compounds, pharmaceutical compositions containing such a compound, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.